Sensei Biotherapeutics Slashes Workforce, Closes R&D Site

Sensei Biotherapeutics Inc SNSE announced a streamlining and realignment of resources.
The company will close its Boston research site and reduce its workforce by approximately 40% to extend Sensei's estimated cash runway into the second half of 2025 versus Q1 of 2025 expected earlier.
The company will maintain its Rockville, Maryland research facility, where antibody discovery and production in support of its lead program SNS-101 and other TMAb programs is conducted while maintaining a smaller business office in the Boston area.
With these announcements, Robert Pierce, Sensei's Chief R&D Officer, will move to a consulting role as a Science Fellow, and Edward van der Horst, Sensei's SVP, Biologics Discovery & Early Development, has been promoted to Chief Scientific Officer.
Sensei continues to advance SNS-101 through investigational new drug-enabling studies and intends to submit an Investigational New Drug application (IND) in or before April 2023.
Price Action: SNSE shares are down 2.60% at $1.50 on the last check Thursday.